Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): A systematic structured review of the literature

Archives of Dermatological Research

Volumn 299, Issue 4, 2007, Pages 169-175

  Weberschock, Tobias Bernd ^a   Müller, Sylke Monina ^a   Boehncke, Sandra ^a   Boehncke, Wolf Henning ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Adverse drug reaction; Coxibs; Intolerance; Non steroidal anti inflammatory drugs; Urticaria

Indexed keywords

CELECOXIB; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; AIRWAY OBSTRUCTION; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; EDEMA; EMBASE; EPISTAXIS; EYELID EDEMA; EYELID WHEAL; GASTROINTESTINAL SYMPTOM; HUMAN; LIP EDEMA; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT HEMORRHAGE; REVIEW; RHINORRHEA; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TONGUE EDEMA; URTICARIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; GASTROINTESTINAL DISEASES; HEMORRHAGE; HUMANS; INFLAMMATION; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY TRACT DISEASES;

EID: 34250727521     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-007-0757-6     Document Type: Review

References (89)

1. Ahlbach S, Usadel KH, Kaufmann R, Boehncke WH (2003) The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs. Med Klin (Munich) 98:242-244
2. Andri L (2001) Safety of celecoxib in patients with ASA/NSAIDs sensitivity (abstract). Allergy 56:223
3. Asero R (2001) Tolerability of rofecoxib. Allergy Eur J Allergy Clin Immunol 56:916-917
4. Asero R (2003) Chronic urticaria with multiple NSAID intolerance: Is tramadol always a safe alternative analgesic? J Investig Allergol Clin Immunol 13:56-59
5. Asero R (2005) Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy 35:713-716
6. Asero R (2006) Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. Ann Allergy Asthma Immunol 97:187-189
7. Asero R, Tedeschi A, Lorini M (2002) Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs. Ann Allergy Asthma Immunol 88:468-472
8. Baldassarre S, Schandene L, Choufani G, Michils A (2006) Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J Allergy Clin Immunol 117:215-217
9. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z (2004) Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 41:67-75
10. Bavbek S, Celik G, Pasaoglu G, Misirligil Z (2006) Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients. J Investig Allergol Clin Immunol 16:57-62
11. Berges-Gimeno MP, Camacho-Garrido E, Garcia-Rodriguez RM, Alfaya T, Martin Garcia C, Hinojosa M (2001) Rofecoxib safe in NSAID hypersensitivity. Allergy Eur J Allergy Clin Immunol 56:1017-1018
12. Bochenek G, Nizankowska E, Mejza F, Sierczynska M, Szczeklik A (2001) Good tolerance of rofecoxib in aspirin-induced asthma. Eur Respir J 18:424s
13. Boehncke S, Boehncke WH (2005) Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs). Dtsch Med Wochenschr 130:2249-2252
14. Carretero P, Perez R, Garces MM (2007) Tolerance to Celecovix in patients with NSAID intolerance (abstract). Allergy 56:222
15. Celik G, Erkekol FO, Bavbek S, Dursun B, Misirligil Z (2005) Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. Ann Allergy Asthma Immunol 95:33-37
16. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D et al (2005) Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma 42:127-131
17. Dahlen B, Szczeklik A, Murray JJ (2001) Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 344:S142
18. Dama AR, Lobefalo G, Bonadona P, Schiappoli M, Crivellaro M (2002) Celecoxib, a new selective COX-2 Inhibitor is a safe alternative drug in NSAID-intolerant patients (abstract). J Allergy Clin Immunol S141
19. Egger M, Smith GD, Sterne JA (2001) Uses and abuses of meta-analysis. Clin Med 1:478-484
20. El Miedany Y, Youssef S, Ahmed I, El Gaafary M (2006) Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 97:105-109
21. Enrique E, Cistero-Bahima A, Miguel-Moncin MM, Alonso R (2000) Rofecoxib should be tried in NSAID hypersensitivity. Allergy 55:1090
22. Fernandez-Melendez S, Miranda A, Carmona MJ, Diaz J, Barcelo JM, Vega JM et al (2002) Tolerance of rofecoxib in patients with adverse reactions to nonsteroidal ant-inflammatory drugs (NSAIDs). J Allergy Clin Immunol 109:S140
23. Garcia-Rodriguez RM, Hinojosa M, Camacho-Garrido E, Berges GP, Martin GC (2002) Celecoxib, safe in NSAID intolerance. Allergy 57:1085-1086
24. Giamarchi D, Escamilla R, Carme S, Krempf M (2004) Selective COX-2 inhibitors: a safety alternative for patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) (abstract). J Allergy Clin Immunol 113:S180
25. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G et al (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475-481
26. Grimm V, Rakoski J, Ring J (2002) Urticaria and angioedema induced by COX-2 inhibitors. J Allergy Clin Immunol 109:370
27. Grob M, Pichler WJ, Wuthrich B (2002) Anaphylaxis to celecoxib. Allergy 57:264-265
28. Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J et al (2003) Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 111:1116-1121
29. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307-314
30. Hinrichs R, Ritzkowsky A, Hunzelmann N, Krieg T, Scharffetter-Kochanek K (2001) Rofecoxib as an alternative in aspirin hypersensitivity. Allergy 56:789
31. Hinrichs R, Ritzkowsky A, Hunzelmann N, Scharffetter-Kochanek K (2001) Cox-2 inhibitors - An alternative in analgesic intolerance. H G Z Hautkr 76:126-127
32. Kalyoncu AF, Karakaya G, Bozkurt B, Artvinli M (2005) A new method of oral drug provocation testing for determining safe alternatives for patients with non-steroidal anti-inflammatory drug intolerance: the triple test. Int Arch Allergy Immunol 138:319-323
33. Karakaya G, Kalyoncu AF (2000) Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics. Allergol Immunopathol (Madr) 28:319-321
34. Kelkar PS, Butterfield JH, Teaford HG (2001) Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol 28:2553-2554
35. Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke W-H (2002) Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis 47:100-102
36. Kosnik M, Music E, Matjaz F, Suskovic S (1998) Relative safety of meloxicam in NSAID-intolerant patients. Allergy 53:1231-1233
37. Kruse R, Ruzicka T, Grewe M (2003) Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib: results of oral provocation tests in patients with NSAID hypersensitivity. Acta Derm Venereol 83:183-185
38. Leong KP, Tang CY, Thong B (2002) The safety of rofecoxib in patients with NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 109:S140
39. Levy MB, Fink JN (2001) Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 87:72-73
40. Liccardi G, Cazzola M, De Giglio C, Manfredi D, Piscitelli E, D'Amato M et al (2005) Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 15:249-253
41. Liccardi G, D'Amato G, Canonica GW, Lobefalo G, Noschese P, Piccolo A et al (2005) Safety of celecoxib in patients with adverse reactions to nimesulide. Allergy 60:708-709
42. Marks F, Harrell K, Fischer R (2001) Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma. South Med J 94:256-257
43. Marshall LL (2005) Angioedema associated with aspirin and rofecoxib. Ann Pharmacother 39:944-948
44. Martin GC, Hinojosa M, Berges P, Camacho E, Garcia RR, Alfaya T et al (2002) Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 121:1812-1817
45. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T (2003) Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 13:20-25
46. Mastalerz L, Sanak M, Gawlewicz A, Gielicz A, Faber J, Szczeklik A (2006) Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria. J Allergy Clin Immunol 118:957-958
47. Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E et al (2004) Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy 59:1133-1134
48. Micheletto C, Tognella S, Guerriero M, Dal Negro R (2006) Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. Allerg Immunol (Paris) 38:10-14
49. Montalvo S, Davila I, Laffond E, Moreno E, Lorente F (2003) Rofecoxib tolerance in patients with NSAID-induced reactions. Alergol Inmunol Clin 18:214-216
50. Morais-Almeida M, Marinho S, Rosa S, Gaspar A, Rosado-Pinto JE (2006) Multiple drug intolerance including etoricoxib. Allergy 61:144-145
51. Munoz-Bellido FJ, Terron M, Leon A (2003) Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. Allergy 58:1072-1075
52. Muratore L, Calogiuri GF, Calcagnile F, Quarta E, Muratore M, Ventura MT et al (2005) Tolerability of etoricoxib in patients affected by non steroidal anti-inflammatory drugs induced urticaria: a single blind placebo study on 37 subjects. Ital J Allergy Clin Immunol 15:73-79
53. Nahar IK, Muqim AT, Al Qhouti BI, Al Herz AA, Shehab DK, Uppal SS et al (2006) The use of etoricoxib in patients with bronchial asthma associated with aspirin sensitivity. Saudi Med J 27:119-120
54. Nekzai E, Hunzelmann N (2002) Intolerance reaction to the cyclooxygenase-2 inhibitor rofecoxib in a patient with analgesic intolerance. H G Z Hautkr 77:246-247
55. Nettis E, Colanardi MC, Ferrannini A, Tursi A (2005) Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 94:29-33
56. Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A (2005) Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 95:438-442
57. Nifosi G (2002) COX-2 inhibitors in allergy. Gazz Med Ital Arch Sci Med 161:109-111
58. Novotna B, Lanikova Z, Dolina J (2002) Tolerance to rofecoxib in patients with aspirin-sensitivity. Alergie 4:149-151
59. Okie S (2005) Raising the safety bar-the FDA's coxib meeting. N Engl J Med 352:1283-1285
60. Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R (2002) Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 32:397-400
61. Passero M, Chowdhry S, Hinojosa M, Martin-Garcia C (2003) Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma [2]. Chest 123:2155-2156
62. Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D et al (2003) Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 132:82-86
63. Quiralte J, Delgado J, Saenz de San PB, Lopez-Pascual E, Nieto MA, Ortega N et al (2004) Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 93:360-364
64. Quiralte J, Saenz de San PB, Florido JJ (2002) Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 89:63-66
65. Rodriguez M, Enrique E, Castello JV, De Mateo JA, Roca B, Malek T (2003) Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge [3]. Ann Allergy Asthma Immunol 91:589
66. Roll A, Wuethrich B, Schmid-Grendelmeier P, Hofbauer G, Ballmer-Weber B (2006) Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. Swiss Med Wkly 136:684-690
67. Sanchez BM, Capriles-Hulett A, Caballero-Fonseca F, Perez CR (2001) Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 87:201-204
68. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F (2001) NSAID hypersensitivity in the COX-2 inhibitor era. Allergy Clin Immunol Int J World Allergy Org 211-218
69. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A (2005) Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 95:154-158
70. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A (2005) Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 94:34-38
71. Schellenberg RR, Isserow SH (2001) Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. N Engl J Med 345:1856
72. Schubert B, Grosse Perdekamp MT, Pfeuffer P, Raith P, Brocker E-B, Trautmann A (2005) Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality? Eur J Dermatol 15:164-167
73. Senna G, Bilo MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P et al (2004) Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Allerg Immunol (Paris) 36:215-218
74. Stevenson DD, Simon RA, Christiansen SC (2000) Lack of cross-reactivity between selective COX-2 inhibitors and aspirin (ASA) in ASA-sensitive asthmatics (abstract). J Allerg Clin Immunol S273
75. Stevenson DD, Simon RA (2001) Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 108:47-51
76. Stevenson DD, Zuraw BL (2003) Pathogenesis of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 24:169-188
77. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M (2001) Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 31:219-225
78. Vaghi A, De Bernardi G, Grassi N, Capato S, Cicchitto G, Sestini P et al (2001) Tolerance of two cox2inhibitors, rofecoxib and celecoxib, in aspirin sensitive asthmatics. Eur Respir J 18:428s
79. Valero A, Baltasar M, Enrique E, Pau L, Dordal MT, Cistero A et al (2002) NSAID-sensitive patients tolerate rofecoxib. Allergy 57:1214-1215
80. Valero A, Enrique E, Baltasar M, Cistero A, Marti E, Picado C (2003) Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions. Med Clin (Barc) 121:695-696
81. Viola M, Quaratino D, Gaeta F, Caringi M, Valluzzi R, Caruso C et al (2005) Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 137:145-150
82. Viola M, Quaratino D, Volpetti S, Gaeta F, Romano A (2006) Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 117:1189-1191
83. Woessner KM, Simon RA, Stevenson DD (2002) The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 46:2201-2206
84. Woessner KM, Simon RA, Stevenson DD (2004) Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 93:339-344
85. Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899
86. Wyplosz B, Vautier S, Lillo-Le Louet A, Capron L (2006) Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone. Br J Clin Pharmacol 61:474
87. Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H (2000) Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma [2]. J Allergy Clin Immunol 106:1201-1202
88. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A (2003) Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 139:1577-1582
89. Zollner TM, Ahlbach S, Kaufmann R, Boehncke WH (2001) Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents. Dtsch Med Wochenschr 126:386-388